Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

NCT07407452 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancers

Interventions

DRUG: Iparomlimab and Tuvonralimab (QL1706)Injection
DRUG: paclitaxel
DRUG: carboplatin
DRUG: Cisplatin
DRUG: Olaparib
DRUG: Cisplatin

Sponsor

Jiangsu Cancer Institute & Hospital